Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (NASDAQ: AMGN) will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 4:00 p.m. ET. The presentation will be delivered by Elliott Levy, senior vice president of R&D Strategy and Operations. Interested parties can access a live audio stream through the Events Calendar on Amgen's website, with a replay available for 90 days post-event.
Amgen focuses on developing innovative therapies to address unmet medical needs, utilizing advanced human genetics to enhance health outcomes.